Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Lisata Therapeutics Inc
Healthcare
P/NCAV
0.45x
Ticker
LSTA
Exchange
NASDAQ
Country
United States
Close
2.65 $
Mkt Cap
21.4M $
EV
-1.2M $
NCAV Burn Rate
27.6%
Current Ratio
8.18
Debt/Equity
0.0
EV/REV
N/Ax
EV/EBIT
0.0x
EV/FCF
0.1x
Dilution
49.3% p.A
Total Net Income
-291.6M $
Cheapness
12.0%
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Its lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate solid tumors. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are not affected. LSTA1 also has the potential to modify the tumor microenvironment (TME). It is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors. Its CD34+ is a cell therapy technology was targeting an array of diseases, among them, critical limb ischemia, coronary microvascular dysfunction, and diabetic kidney disease.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average